research Śródskórne iniekcje acetonidu triamcynolonu w leczeniu Zespołu Grahama-Little’a — opis przypadku
Intralesional triamcinolone acetonide can effectively limit the progression of GLPLS.
Search
for
Sort by
Research
390-420 / 1000+ resultsresearch Berardinelli–Seip syndrome
Early diagnosis and treatment are crucial for managing Berardinelli–Seip syndrome.
research Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
research Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial
Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
research La voie de la PGI2 pour améliorer la cicatrisation des plaies du pied diabétique
Targeting the PGI2 pathway may help heal diabetic foot ulcers.
research Improved Efficacy of Low-Dose Spironolactone and Metformin Combination Than Either Drug Alone in the Management of Women With Polycystic Ovary Syndrome (PCOS): A Six-Month, Open-Label Randomized Study
Taking low-dose spironolactone and metformin together works better for PCOS symptoms than either drug alone.
research Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance
Metformin helps with PCOS symptoms no matter the patient's initial insulin resistance or weight.
research Essitalopram kullanımıyla gelişen ve duloksetine geçilmesiyle gerileyen alopesi: Olgu sunumu
Switching from escitalopram to duloxetine improved hair loss.
research Simvastatin-induced myoglobinuric acute kidney injury following ciclosporin treatment for alopecia universalis
Combining ciclosporin and simvastatin can cause severe kidney damage.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Metformin and Malignant Tumors: Not Over the Hill
Metformin, a diabetes drug, may help prevent and treat various cancers, but more research is needed.
research Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report
Tirzepatide improved symptoms and hair regrowth in a man with folliculitis decalvans.
research Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring
Ruxolitinib effectively and safely regrows hair in alopecia patients.
research When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome?
Metformin should be used for PCOS mainly in those with glucose intolerance, and has limited benefits for infertility or hirsutism.
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research Baricitinib (Olumiant)
Olumiant should be covered for severe alopecia areata if certain conditions are met.
research Baricitinib Treatment Increases Eyebrow and Eyelash Regrowth Up to 52 Weeks
research Antidiabetic and Wound Healing Effects of Smeathxanthone A
Smeathxanthone A improves wound healing and lowers blood sugar in diabetic mice.
research Inositol and FSH: A new frontier for the androgenetic alopecia treatment
Inositol and folic acid treatment significantly reduced hair loss and other symptoms in patients with androgenetic alopecia, but more research is needed for confirmation.
research 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research 43018 Safety Analysis of Baricitinib in Adult Patients with Severe Alopecia Areata From 2 Randomized Clinical Trials over a Median of 1.6 years and up to 3.6 Years of Exposure
Baricitinib is a safe and effective treatment for severe alopecia areata.
research Tannic acid and silicate-functionalized polyvinyl alcohol–hyaluronic acid hydrogel for infected diabetic wound healing
The hydrogel helps heal diabetic wounds by reducing infection and inflammation.
research Teriflunomide: a novel oral treatment for relapsing multiple sclerosis
Teriflunomide is an effective and safe first-line oral treatment for relapsing multiple sclerosis.
research Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
research Baricitinib-Loaded Separable Microneedle Array Patch (S-Map) Based on Hyaluronic Acid for Alopecia Areata Therapy
The patch effectively promotes hair growth for alopecia areata without pain.
research Antigen-Specific Regulatory T Cells and Low Dose of IL-2 in Treatment of Type 1 Diabetes
Using low-dose IL-2 to increase regulatory T cells might be a safe way to treat type 1 diabetes without severe side effects.
research Drug pipeline 2Q22 — a downturn in approvals
Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.
research Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.
research β‐Sitosterol—Dietary sources and role in cancer and diabetes management
β-Sitosterol may help prevent heart disease, cancer, and diabetes, but more human studies are needed.